SEC Form 4 · accession 0001209191-18-035378
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabriel Leung
Director
Period of report
May 31, 2018
Accepted (ET)
Jun 4, 2018 · 8:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $31.45 | May 31, 2018 | A | 12,345 | A | — | May 31, 2028 | Ordinary Shares | 12,345 | 12,345 | D |
| Restricted Stock UnitF2,F3 | — | May 31, 2018 | A | 6,145 | A | — | — | Ordinary Shares | 6,145 | 6,145 | D |
Explanation of responses
- F1Options to buy 12,345 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.
- F2Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
- F3These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.